Tuesday, Medtronic Plc (NYSE:MDT) reported first-quarter 2025 sales of $7.92 billion, beating the consensus of $7.89 billion.
The medical device maker reported adjusted EPS of $1.23, beating the consensus of $1.20. Revenue increased 2.8% year over year, as reported, and 5.3% organic.
The company said multiple franchises delivered, with accelerating growth in Cardiac Ablation Solutions and Neuromodulation and continued strength in Spine, Structural Heart, and Diabetes.
Also Read: Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers.
Cardiovascular segment revenue reached $3.01 billion, up 5.5% year over year as reported, and increased 6.9% organically, with high-single-digit increases in Cardiac Rhythm & Heart Failure ...